Gilead Sciences, Inc. (GILD)
168.06
+0.11
(+0.07%)
USD |
NASDAQ |
Nov 13, 16:00
167.94
-0.12
(-0.07%)
After-Hours: 19:59
Gilead Sciences Enterprise Value : 226.62B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 226.62B |
| November 11, 2026 | 228.83B |
| November 10, 2026 | 230.24B |
| November 09, 2026 | 228.32B |
| November 06, 2026 | 225.31B |
| November 05, 2026 | 226.15B |
| November 04, 2026 | 234.72B |
| November 03, 2026 | 226.03B |
| November 02, 2026 | 229.57B |
| October 30, 2026 | 230.01B |
| October 29, 2026 | 223.72B |
| October 28, 2026 | 215.76B |
| October 27, 2026 | 215.61B |
| October 26, 2026 | 215.13B |
| October 23, 2026 | 211.84B |
| October 22, 2026 | 213.27B |
| October 21, 2026 | 208.78B |
| October 20, 2026 | 212.42B |
| October 19, 2026 | 208.15B |
| October 16, 2026 | 212.03B |
| October 15, 2026 | 213.49B |
| October 14, 2026 | 208.74B |
| October 13, 2026 | 201.76B |
| October 12, 2026 | 204.88B |
| October 09, 2026 | 205.80B |
| Date | Value |
|---|---|
| October 08, 2026 | 200.75B |
| October 07, 2026 | 200.44B |
| October 06, 2026 | 197.18B |
| October 05, 2026 | 197.68B |
| October 02, 2026 | 197.82B |
| October 01, 2026 | 201.24B |
| September 30, 2026 | 203.17B |
| September 29, 2026 | 209.02B |
| September 28, 2026 | 210.17B |
| September 25, 2026 | 208.58B |
| September 24, 2026 | 207.05B |
| September 23, 2026 | 209.13B |
| September 22, 2026 | 210.74B |
| September 21, 2026 | 208.12B |
| September 18, 2026 | 207.57B |
| September 17, 2026 | 208.53B |
| September 16, 2026 | 204.55B |
| September 15, 2026 | 202.84B |
| September 14, 2026 | 202.97B |
| September 11, 2026 | 199.64B |
| September 10, 2026 | 200.99B |
| September 09, 2026 | 202.03B |
| September 08, 2026 | 203.26B |
| September 04, 2026 | 208.66B |
| September 03, 2026 | 208.94B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 91.75B |
| AbbVie, Inc. | 590.62B |
| Biogen, Inc. | 43.52B |
| Vertex Pharmaceuticals, Inc. | 137.73B |
| Amgen, Inc. | 293.45B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.429B |
| Revenue (Quarterly) | 8.304B |
| Total Expenses (Quarterly) | 5.875B |
| EPS Diluted (Quarterly) | 1.942 |
| Gross Profit Margin (Quarterly) | 81.09% |
| Profit Margin (Quarterly) | 29.25% |
| Earnings Yield | -1.87% |
| Operating Earnings Yield | 5.68% |
| Normalized Earnings Yield | 2.720 |